Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Self-Collected versus Healthcare Worker-Collected Swabs in the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Flow Complexity Estimation in Dysfunctional Arteriovenous Dialysis Fistulas using Vector Flow Imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Our aim was to investigate whether dynamic contrast-enhanced ultrasound (DCE-US) can detect early changes in perfusion of colorectal liver metastases after initiation of chemotherapy. Newly diagnosed patients with colorectal cancer with liver metastases were enrolled in this explorative prospective study. Patients were treated with capecitabine or 5-fluorouracil-based chemotherapy with or without bevacizumab. DCE-US was performed before therapy (baseline) and again 10 days after initiation of treatment. Change in contrast-enhancement in one liver metastasis (indicator lesion) was measured. Treatment response was evaluated with a computed tomography (CT) scan after three cycles of treatment and the initially observed DCE-US change of the indicator lesion was related to the observed CT response. Eighteen patients were included. Six did not complete three series of chemotherapy and the evaluation CT scan, leaving twelve patients for analysis. Early changes in perfusion parameters using DCE-US did not correlate well with subsequent CT changes. A subgroup analysis of eight patients receiving bevacizumab, however, demonstrated a statistically significant correlation (p = 0.045) between early changes in perfusion measures of peak enhancement at DCE-US and tumor shrinkage at CT scan. The study indicates that early changes in DCE-US perfusion measures may predict subsequent treatment response of colorectal liver metastases in patients receiving bevacizumab.

OriginalsprogEngelsk
TidsskriftDiagnostics
Vol/bind7
Udgave nummer2
Sider (fra-til)Pii:E35
ISSN2075-4418
DOI
StatusUdgivet - 2017

ID: 51803398